Loading page
Loading page
Loading substance route
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Chronic use is considered moderately addictive with a high potential for abuse and may cause psychological dependence. Cravings may develop with regular use, and users may experience difficulty stopping once a pattern of use has been established.
Withdrawal effects may occur when regular users suddenly stop, though these appear to primarily involve neurotransmitter depletion symptoms such as anxiety, depression, cognitive fatigue, and irritability rather than severe physical withdrawal.
The exact toxic dosage is unknown. Toxicity and long-term health effects have not been studied in any scientific context due to the substance's very limited history of human usage.
Abuse at high dosages for prolonged periods can potentially result in stimulant psychosis presenting with paranoia, hallucinations, or delusions. Based on data from related amphetamine-class stimulants, approximately 5-15% of users who develop stimulant psychosis may not fully recover. Psychosis is unlikely with occasional use at moderate doses.
Butylone was first synthesized in 1967 by Koeppe, Ludwig, and Zeile, who documented their work in a paper from that year. Following its initial synthesis, the compound remained an obscure product of academic chemistry for nearly four decades, receiving little attention outside of laboratory…
Prohibited under the Neue-Psychoaktive-Substanzen-Gesetz (New Psychoactive Substances Act). Possession, production, and sale are illegal.
Listed as a Schedule I substance under the Controlled Drugs and Substances Act. Manufacturing, possession, and distribution carry significant criminal penalties.
Scheduled under the government decree on psychoactive substances banned from the consumer market.
Listed in Anlage II of the Betäubungsmittelgesetz (Narcotics Act) since July 26, 2012. Manufacturing, possession, import, export, purchase, sale, procurement, and dispensing without a license are prohibited.
Designated a controlled substance under Japanese pharmaceutical and narcotics regulations.
Listed as a controlled substance under Polish narcotics legislation.
Specifically named as a controlled substance in Verzeichnis D of the Swiss narcotics regulations.
Listed as a Schedule I controlled substance under the Controlled Substances Act. Additionally, as a structural analogue of MDMA and methylone, it may be prosecuted under the Federal Analogue Act when intended for human consumption.
Controlled since September 7, 2018 under a blanket ban covering all cathinone analogues, appended to Portaria SVS/MS nº 344. Possession, use, and distribution are illegal.
Designated a controlled substance as of October 2015 under national drug control legislation.
Classified as a stupéfiant (recognized drug of abuse) under French drug legislation. Possession, purchase, sale, and manufacture are prohibited.
Regulated as a controlled substance under national drug control legislation.
Classified as a controlled substance under Norwegian drug control legislation.
Added to Schedule I (substances without accepted medical use) as of February 1, 2010. Listed by the Medical Products Agency in regulation LVFS 2022:48 under the designation Butylon.
Controlled as a Class B substance under the Misuse of Drugs Act 1971 through the cathinone catch-all clause, which covers synthetic cathinone derivatives.
18 sources cited